Among these molecules, neuroprotective molecules, such as growth hormone (GH), insulin-like growth factor-1 (IGF-1), and nerve growth factor, have been tested in SCA3 animal models and in humans through clinical trials and have displayed potential therapeutic effects in patients with SCA3 [6,7]. This evidence concerns the gene IGF1 and Spinocerebellar ataxia type 3.